Sacubitril/Valsartan Does Not Change the Use and Dose of Loop Diuretics in Patients With Heart Failure With Reduced Ejection Fraction
Journal of Pharmacy Practice · 2024
DOI: 10.1177/08971900231177202 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy Practice, 2024. Verfasst von Kazuhiko Kido und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Morgantown, WV, USA. Hauptthemen laut MEDLINE: Heart Failure, Aminobutyrates, Valsartan, Stroke Volume. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben. Gefördert von: NIH Clinical Center.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
There is no standard approach for managing the use or dose of loop diuretics after initiating sacubitril/valsartan.
Objective
To investigate longitudinal trends in loop diuretic therapy use and doses during the initial 6 months following sacubitril/valsartan initiation.
Methods
This retrospective cohort study included adult patients who were initiated on sacubitril/valsartan in cardiology clinics. Inclusion criteria were patients diagnosed with heart failure with reduced ejection fraction (ejection fraction ≤40%) and initiated on sacubitril/valsartan in an outpatient setting. We investigated longitudinal trends in the prevalence of loop diuretic use and furosemide equivalent dose at baseline, 2 weeks, 1 month, 3 month and 6 months following sacubitril/valsartan initiation.
Results
A total of 427 patients were included in the final cohort. Compared to the baseline loop diuretic use and dose, there were no significant longitudinal changes in the prevalence of loop diuretic use or the furosemide equivalent dose over the 6 months following sacubitril/valsartan initiation. The use of sacubitril/valsartan was not significantly associated with reductions in the use or dose of loop diuretics over a 6-month follow-up period.
Conclusion
The use of sacubitril/valsartan did not significantly change the use or dose of loop diuretics over 6-month follow-up period. Initiation of sacubitril/valsartan may not need a pre-emptive loop diuretic dose reduction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Morgantown, WV, USA.
- Division of Cardiology, Department of Medicine, West Virginia University, Morgantown, Morgantown, WV, USA.
- Tokyo Jikei University School of Medicine, Tokyo, Japan.
- Clinical and Translational Science, West Virginia University, Morgantown, WV, USA.
ORCID-Profile: Kazuhiko Kido, Marco Caccamo, Lyn Yuen Choo
Förderung
- NIH Clinical Center
Zitieren
APA
Kido, K., Bianco, C., Caccamo, M., Hashiguchi, M., Choo, L. Y., & Sokos, G. (2024). Sacubitril/Valsartan Does Not Change the Use and Dose of Loop Diuretics in Patients With Heart Failure With Reduced Ejection Fraction. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900231177202
Vancouver
Kido K, Bianco C, Caccamo M, Hashiguchi M, Choo LY, Sokos G. Sacubitril/Valsartan Does Not Change the Use and Dose of Loop Diuretics in Patients With Heart Failure With Reduced Ejection Fraction. Journal of Pharmacy Practice. 2024. doi:10.1177/08971900231177202
BibTeX
@article{Kido2024,
author = {Kido, Kazuhiko and Bianco, Christopher and Caccamo, Marco and Hashiguchi, Masayuki and Choo, Lyn Yuen and Sokos, George},
title = {Sacubitril/Valsartan Does Not Change the Use and Dose of Loop Diuretics in Patients With Heart Failure With Reduced Ejection Fraction},
journal = {Journal of Pharmacy Practice},
year = {2024},
doi = {10.1177/08971900231177202}
}
EUVIMED